Login
$YARW
$13.93 +$0.00 (0.0%) After hours

$YARW SEC Filings

Filed On Filing
16 Nov 2026 SCHEDULE 13G
16 Nov 2026 SCHEDULE 13G/A
13 Nov 2026 FORM S-8
13 Nov 2026 SCHEDULE 13G/A
13 Nov 2026 SCHEDULE 13G
13 Nov 2026 10-Q
12 Nov 2026 8-K: Results of Operations and Financial Condition

Enrollment ongoing in the Phase 2a/2b trial evaluating YB-101, a potential first-in-class anti-TSHR antibody, in patients with Graves’ disease (with or without concomitant thyroid eye disease); Phase 2a topline results expected in the se...

30 Oct 2026 Form 4: Payton Lori, Chief Development Officer

Granted 99,827 Stock Option (Right to Buy)

30 Oct 2026 Form 4: Alford Rachael, Chief Operating Officer

Granted 89,844 Stock Option (Right to Buy)

30 Oct 2026 Form 4: Frey Rebecca, Director

Granted 465,857 Stock Option (Right to Buy)

30 Oct 2026 Form 4: Ryder Steven, Chief Medical Officer

Granted 113,137 Stock Option (Right to Buy)

30 Oct 2026 Form 4: Zeronda Tyler, Chief Financial Officer

Granted 156,115 Stock Option (Right to Buy)

07 Oct 2026 SCHEDULE 13G
17 Sep 2026 SCHEDULE 13G
14 Sep 2026 8-K: Entry into a Material Definitive Agreement

Introductory. Yarrow Bioscience, Inc., a Delaware corporation (the “Company”), proposes to issue and sell to the several underwriters named in Schedule A (the “Underwriters”) an aggregate of 5,769,231 shares of its common stock, par valu...

11 Sep 2026 424B5
11 Sep 2026 424B5
10 Sep 2026 8-K: Other Events

Yarrow Bioscience, Inc. (“Yarrow”) is a clinical-stage biotechnology company focused on developing transformative therapies for autoimmune thyroid diseases. Yarrow’s lead product candidate, YB-101 (also known as GenSci098), is a humanize...

19 Aug 2026 EFFECT
14 Aug 2026 SCHEDULE 13G

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support